<html>

  <head>
    <title>pvct8k121107.htm</title>
<!-- Licensed to: Baker, Donelson, Bearman, Caldwell & Berkowitz-->
<!-- Document Created using EDGARizer 4.0.1.0 -->
<!-- Copyright 2007 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman;"><strong>FORM
      8-K</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>CURRENT
      REPORT</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>PURSUANT
      TO SECTION 13 OR 15(d) OF THE</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>SECURITIES
      EXCHANGE ACT OF 1934</strong></font></div>
    <div><br></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Date
      of
      Report (date of earliest event reported):&#160;&#160;<u> December 10,
      2007</u></font></div>
    <div><br></div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman;"><strong>PROVECTUS
      PHARMACEUTICALS, INC.</strong></font></div>
    <div><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="bottom" width="31%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;"><strong>Nevada</strong></font></div>
            </td>
            <td valign="bottom" width="26%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;"><strong>0-9410</strong></font></div>
            </td>
            <td valign="bottom" width="29%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;"><strong>90-0031917</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" width="31%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">(State
                or other jurisdiction of incorporation)</font></div>
            </td>
            <td valign="top" width="26%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">(Commission
                File Number)</font></div>
            </td>
            <td valign="top" width="29%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">(I.R.S.
                Employer Identification No.)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>7327
      Oak Ridge Hwy., Knoxville, Tennessee 37931</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">(Address
      of Principal Executive Offices)</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><font style="DISPLAY: inline; FONT-FAMILY: CG Times (W1), Times New Roman, serif;">&#160;</font><strong>(866)
      594-5999</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">(Registrant&#8217;s
      Telephone Number, Including Area Code)</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Check
      the
      appropriate box if the Form 8-K filing is intended to simultaneously satisfy
      the
      filing obligation of the registrant under any of the following
      provisions:</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">[&#160;&#160;]
      Written communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">[&#160;&#160;]
      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">[&#160;&#160;]
      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
      Act
      (17 CFR 240.14d-2(b))</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">[&#160;&#160;]
      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
      Act
      (17 CFR.13e-4(c))</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font id="TAB1" style="MARGIN-LEFT: 468pt;"></font><br></div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div>&#160;</div>
    <div>
      <div align="left">
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Item
            5.03&#160;&#160;Amendments to Articles of Incorporation or Bylaws; Change in
            Fiscal Year</font></div>
        </div>
      </div>
    </div>
    <div><br><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;
</font>On
      December 10, 2007, the Board of
      Directors of Provectus Pharmaceuticals, Inc. (the &#8220;Company&#8221;), pursuant to the
      authority granted in Article 7 of the Company&#8217;s Bylaws, amended the Bylaws for
      the purpose of complying with the eligibility requirements of the Direct
      Registration System for the Company&#8217;s securities.&#160;&#160;The Board of
      Directors adopted the following amendment:</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Article
      6
      of the Corporation&#8217;s Bylaws is hereby deleted in its entirety and the following
      is substituted in lieu thereof:</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">ARTICLE
      6</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">SHARES
      OF
      STOCK</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><font id="TAB1" style="MARGIN-LEFT: 36pt;"></font>6.01.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Shares
      of the Corporation may be owned either in (i) certificated form, in which
      ownership of the shares is represented by a physical certificate, or (ii)
      uncertificated form, pursuant to a Direct Registration System in connection
      with
      which shares will be held in book-entry form and no physical certificate will
      be
      printed.&#160;&#160;Each shareholder shall be entitled upon request to a
      certificate or certificates which shall represent and certify the number and
      kind and class of shares owned by him in the Corporation.&#160;&#160;Each
      certificate shall be signed by the President&#160;&#160;or Vice President and by
      the Secretary or the Assistant Secretary and shall be sealed with the corporate
      seal.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><font id="TAB1" style="MARGIN-LEFT: 36pt;"></font>6.02.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The
      signatures on a certificated stock certificate may be either manual or facsimile
      signatures and the seal may be either facsimile or any other form of
      seal.&#160;&#160;In case any officer who has signed any certificates ceases to
      be an officer of the Corporation before the certificate is issued, the
      certificate may nevertheless be issued by the Corporation with the same effect
      as if the officer had not ceased to be such officer as of the date of its
      issue.&#160;&#160;All certificates surrendered to the Corporation for transfer
      shall be cancelled and no new certificate shall be issued until the former
      certificate for a like number of shares shall have been surrendered and
      cancelled, except that in case of a lost, destroyed or mutilated certificate,
      a
      new one may be issued therefor upon such terms and indemnity to the Corporation
      as the Board of Directors may prescribe.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><font id="TAB1" style="MARGIN-LEFT: 36pt;"></font>6.03&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Transfers
      of shares shall be made either (i) if in certificated form, by a transfer of
      the
      stock certificate representing the shares, or (ii) if in uncertificated form,
      by
      electronic book-entry transfer pursuant to a Direct Registration
      System.&#160;&#160;Upon surrender to the Corporation or the transfer agent of
      the Corporation of a certificate for shares duly endorsed or accompanied by
      proper evidence of succession, assignment or authority to transfer, or upon
      transfer of book-entry ownership, it shall be the duty of the Corporation to
      issue new shares to the person entitled thereto, cancel the old shares and
      record the transaction upon its books.&#160;&#160;The person registered on the
      books of the Corporation as the owner of any shares of stock shall be entitled
      to all the rights of ownership with respect to such shares.</font></div>
    <div><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><font id="TAB1" style="MARGIN-LEFT: 36pt;"></font>6.04&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The
      consideration for the issuance of shares may be paid, in whole or in part,
      in
      money, in other property, tangible or intangible, or in labor or services
      actually performed for the Corporation.&#160;&#160;When payment of the
      consideration for which shares are to be issued shall have been received by
      the
      Corporation, such shares shall be deemed to be fully paid and
      nonassessable.&#160;&#160;In the absence of fraud in the transaction, the
      judgment of the Board of Directors as to the value of the consideration received
      for shares shall be conclusive.&#160;&#160;No share shall be issued until the
      share is fully paid.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><font id="TAB1" style="MARGIN-LEFT: 36pt;"></font>6.05&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Shares
      of capital stock of the Corporation shall not be issued except on a majority
      vote of the Board of Directors.&#160;&#160;The vote of each director shall
      appear in the written minutes of each Board of Directors&#8217; meeting in which the
      issuance of shares was approved.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><font id="TAB1" style="MARGIN-LEFT: 36pt;"></font>6.06&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The
      holders of the capital stock of the Corporation shall be entitled to receive,
      when and as declared by the Board of Directors, solely out of unreserved and
      unrestricted earned surplus, dividends payable either in cash, in property,
      or
      in shares of capital stock.&#160;&#160;No dividends shall be paid upon the
      capital stock in any medium if the source out of which it is proposed to pay
      the
      dividend is due to or arises from unrealized appreciation in value or from
      a
      revaluation of assets, or if the Corporation is, or is thereby rendered,
      incapable of paying its debts as they become due in the usual course of its
      business.</font></div>
    <div><br></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><font id="TAB1" style="MARGIN-LEFT: 36pt;"></font>The
      Company will file its Bylaws,as
      amended, in its entirety as an exhibit to its Annual Report on Form 10K-SB
      for
      the year ended December 31, 2007.</font></div>
    <div><br></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>SIGNATURE</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><font id="TAB1" style="MARGIN-LEFT: 36pt;"></font>Pursuant
      to the requirements of the
      Securities Exchange Act of 1934, the registrant has duly caused this report
      to
      be signed on its behalf by the undersigned hereunto duly
      authorized.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Dated:&#160;&#160;December
      11, 2007</font></div>
    <div><br></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><font id="TAB1" style="MARGIN-LEFT: 108pt;"></font><font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;
</font>PROVECTUS
      PHARMACEUTICALS,
      INC.</font></div>
    <div><br></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><font id="TAB1" style="MARGIN-LEFT: 180pt;"></font><font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;</font>&#160;
By:
<u>/s/
      Peter R.
      Culpepper</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><font id="TAB1" style="MARGIN-LEFT: 216pt;"></font><font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
      Name: Peter R. Culpepper</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><font id="TAB1" style="MARGIN-LEFT: 216pt;"></font><font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt;">&#160;&#160;&#160;</font>Title:&#160;
Chief
      Financial Officer</font></div><br><br></body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "pvct8k121107.htm", "description": "PVCT 8-K 12-11-07", "secsgml_size_bytes": 22799}]
{"company-data": {"conformed-name": "PROVECTUS PHARMACEUTICALS INC", "cik": "0000315545", "assigned-sic": "2834", "irs-number": "900031917", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-09410", "film-number": "071301315"}, "business-address": {"street1": "7327 OAK RIDGE HWY", "street2": "SUITE B", "city": "KNOXVILLE", "state": "TN", "zip": "37931", "phone": "865-769-4011"}, "mail-address": {"street1": "7327 OAK RIDGE HWY", "street2": "SUITE B", "city": "KNOXVILLE", "state": "TN", "zip": "37931"}, "former-company": [{"former-conformed-name": "ZAMAGE DIGITAL IMAGING INC", "date-changed": "20011126"}, {"former-conformed-name": "SPM GROUP INC", "date-changed": "19920703"}]}
pvct8k121107.htm
UNITED
      STATES
SECURITIES
      AND EXCHANGE COMMISSION
Washington,
      D.C. 20549
FORM
      8-K
CURRENT
      REPORT
PURSUANT
      TO SECTION 13 OR 15(d) OF THE
SECURITIES
      EXCHANGE ACT OF 1934
Date
      of
      Report (date of earliest event reported):
December 10,
      2007
PROVECTUS
      PHARMACEUTICALS, INC.
Nevada
0-9410
90-0031917
(State
                or other jurisdiction of incorporation)
(Commission
                File Number)
(I.R.S.
                Employer Identification No.)
7327
      Oak Ridge Hwy., Knoxville, Tennessee 37931
(Address
      of Principal Executive Offices)
(866)
      594-5999
(Registrant's
      Telephone Number, Including Area Code)
Check
      the
      appropriate box if the Form 8-K filing is intended to simultaneously satisfy
      the
      filing obligation of the registrant under any of the following
      provisions:
[  ]
      Written communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)
[  ]
      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)
[  ]
      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
      Act
      (17 CFR 240.14d-2(b))
[  ]
      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
      Act
      (17 CFR.13e-4(c))
Item
            5.03  Amendments to Articles of Incorporation or Bylaws; Change in
            Fiscal Year
On
      December 10, 2007, the Board of
      Directors of Provectus Pharmaceuticals, Inc. (the "Company"), pursuant to the
      authority granted in Article 7 of the Company's Bylaws, amended the Bylaws for
      the purpose of complying with the eligibility requirements of the Direct
      Registration System for the Company's securities.  The Board of
      Directors adopted the following amendment:
Article
      6
      of the Corporation's Bylaws is hereby deleted in its entirety and the following
      is substituted in lieu thereof:
ARTICLE
      6
SHARES
      OF
      STOCK
6.01.         Shares
      of the Corporation may be owned either in (i) certificated form, in which
      ownership of the shares is represented by a physical certificate, or (ii)
      uncertificated form, pursuant to a Direct Registration System in connection
      with
      which shares will be held in book-entry form and no physical certificate will
      be
      printed.  Each shareholder shall be entitled upon request to a
      certificate or certificates which shall represent and certify the number and
      kind and class of shares owned by him in the Corporation.  Each
      certificate shall be signed by the President  or Vice President and by
      the Secretary or the Assistant Secretary and shall be sealed with the corporate
      seal.
6.02.         The
      signatures on a certificated stock certificate may be either manual or facsimile
      signatures and the seal may be either facsimile or any other form of
      seal.  In case any officer who has signed any certificates ceases to
      be an officer of the Corporation before the certificate is issued, the
      certificate may nevertheless be issued by the Corporation with the same effect
      as if the officer had not ceased to be such officer as of the date of its
      issue.  All certificates surrendered to the Corporation for transfer
      shall be cancelled and no new certificate shall be issued until the former
      certificate for a like number of shares shall have been surrendered and
      cancelled, except that in case of a lost, destroyed or mutilated certificate,
      a
      new one may be issued therefor upon such terms and indemnity to the Corporation
      as the Board of Directors may prescribe.
6.03           Transfers
      of shares shall be made either (i) if in certificated form, by a transfer of
      the
      stock certificate representing the shares, or (ii) if in uncertificated form,
      by
      electronic book-entry transfer pursuant to a Direct Registration
      System.  Upon surrender to the Corporation or the transfer agent of
      the Corporation of a certificate for shares duly endorsed or accompanied by
      proper evidence of succession, assignment or authority to transfer, or upon
      transfer of book-entry ownership, it shall be the duty of the Corporation to
      issue new shares to the person entitled thereto, cancel the old shares and
      record the transaction upon its books.  The person registered on the
      books of the Corporation as the owner of any shares of stock shall be entitled
      to all the rights of ownership with respect to such shares.
6.04           The
      consideration for the issuance of shares may be paid, in whole or in part,
      in
      money, in other property, tangible or intangible, or in labor or services
      actually performed for the Corporation.  When payment of the
      consideration for which shares are to be issued shall have been received by
      the
      Corporation, such shares shall be deemed to be fully paid and
      nonassessable.  In the absence of fraud in the transaction, the
      judgment of the Board of Directors as to the value of the consideration received
      for shares shall be conclusive.  No share shall be issued until the
      share is fully paid.
6.05           Shares
      of capital stock of the Corporation shall not be issued except on a majority
      vote of the Board of Directors.  The vote of each director shall
      appear in the written minutes of each Board of Directors' meeting in which the
      issuance of shares was approved.
6.06           The
      holders of the capital stock of the Corporation shall be entitled to receive,
      when and as declared by the Board of Directors, solely out of unreserved and
      unrestricted earned surplus, dividends payable either in cash, in property,
      or
      in shares of capital stock.  No dividends shall be paid upon the
      capital stock in any medium if the source out of which it is proposed to pay
      the
      dividend is due to or arises from unrealized appreciation in value or from
      a
      revaluation of assets, or if the Corporation is, or is thereby rendered,
      incapable of paying its debts as they become due in the usual course of its
      business.
The
      Company will file its Bylaws,as
      amended, in its entirety as an exhibit to its Annual Report on Form 10K-SB
      for
      the year ended December 31, 2007.
SIGNATURE
Pursuant
      to the requirements of the
      Securities Exchange Act of 1934, the registrant has duly caused this report
      to
      be signed on its behalf by the undersigned hereunto duly
      authorized.
Dated:  December
      11, 2007
PROVECTUS
      PHARMACEUTICALS,
      INC.
By:
/s/
      Peter R.
      Culpepper
Name: Peter R. Culpepper
Title: 
Chief
      Financial Officer